What Wall Street is saying about AVEO Pharmaceuticals, Inc. (AVEO)

What Wall Street is saying about AVEO Pharmaceuticals, Inc. (AVEO)

What Wall Street is saying about AVEO Pharmaceuticals, Inc. (AVEO)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock is presently standing at about $2.22 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 2 analysts covering the company is $2.50, which suggests the stock could still rise over 11 percent. The highest analyst price target is $3.00, which implies a rally of 65 percent. And a quick view of analyst notes show that 1 are rating the stock a buy while 1 rate AVEO a strong buy. There are 0 equity research firms advocating a Hold and 0 consider it Sell.

Piper Jaffray analysts provided their view on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently. The rating firm issued a Overweight rating to this company in a research note released on May 19, 2016. FBR Capital analysts disclosed their opinion on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently. The rating firm gave a Outperform rating to this stock in a research note published on Mar 30, 2016. According to a research note disclosed on Mar 09, 2015, analysts at RBC Capital Mkts have upped their rating on these shares from Underperform to Sector Perform.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its 10% Owner Sonsini Peter W. Purchased 16,362,694 company shares for 3,000,000, in a transaction on Mar 28. Following the transaction, the 10% Owner is left with a stake of 6,000,000 shares, currently valued at $13,320,000. Meanwhile, 10% Owner Viswanathan Ravi purchased 16,362,694 shares worth $3,000,000, through a transaction dated Mar 28. Following the completion of the transaction, the insider is left with a stake of 6,000,000 shares, amounting $13,320,000. AVEO 10% Owner Sakoda Jon also purchased 16,362,694 shares, at a stock price of $0.50. This transaction occurred on Mar 28 totals $3,000,000. After this transaction, the insider’s stake stands at 6,000,000 shares, with a market value of $13,320,000.

Executives hold 2.15 percent of the stock. NEA MANAGEMENT COMPANY, LLC is one of the biggest insider owners in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 16,362,694 shares which have current market value of around $36,325,181.PERCEPTIVE ADVISORS LLC is another major inside shareholder in the company. The insider owns 5,108,808 shares as of 03/31/2017, currently worth $11,341,554. ARMISTICE CAPITAL, LLC is ranked as third insider holder of the stock. This insider holds 4,800,000 shares with a market value around $10,656,000 as of recent close.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Earnings Outlook

In AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s latest quarter, EPS moved to $-0.12 from $-0.07 in preceding quarter and revenues reached at $2.53M compared to $0.13M. Analysts had expected AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to post net income of about $-0.12 per share on $0.12M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.17 to $-0.09. That is compared with the $-0.13 in EPS it reported during the same period a year ago.

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.